REHOVOT, Israel, July 5, 2022
/PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company
developing innovative microbiome-based therapeutics, and a
subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today
announced it will be presenting at Microbiome Connect Europe taking
place between July 6-7,
2022, in Amsterdam,
Netherlands.
The Annual Microbiome Connect Europe is dedicated to showcasing
the leading drug development and consumer product platforms
applying live microbial consortia, engineered microbes, and
microbial-derived metabolites for therapeutic and health
applications in patients and consumers.
In attendance will be Dr. Shiri Meshner, VP R&D at Biomica,
who will be presenting both on behalf of the Company and as part of
a panel at the conference.
On July 6, 2022, Dr. Meshner will
be part of a panel entitled, Gut Microbiota-Mediated Modulation
of Cancer Progression and Therapy Efficacy, which is scheduled
for 11:30am CET.
On July 7, 2022, at 3:45pm CET, Dr. Meshner will be providing an
overview and recent updates on Biomica's BMC128 in a talk entitled,
BMC128 - A rationally designed live bacterial consortium for the
potentiation of immune checkpoint therapy in solid tumors.
Dr. Meshner will also be available for one-on-one meetings at
the conference, and those interested should be in touch with the
investor or public relations team.
About Biomica
Biomica is an emerging biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing a dedicated
Computational Predictive Biology platform (CPB), licensed from
Evogene. Biomica aims to identify and characterize disease-related
microbiome entities and to develop novel therapeutics based on
these understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more
information, please visit www.biomicamed.com.
Contacts
Lital Mamon
Head of
Marketing and PR
E: IR@evogene.com
T: +972-8-931-2097
Kenny Green
US Investor
Relations
E: IR@evogene.com
T: +1 212 378 8040
Logo:
https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-microbiome-connect-europe-2022-301580422.html
SOURCE Biomica Ltd.